Takeaway
- A weekly injection of 4 or 6 mg efpeglenatide was associated with a lower risk for cardiovascular events than placebo in patients with type 2 diabetes (T2D) and either a history of cardiovascular (CV) disease or current kidney disease plus at least 1 additional CV risk factor.
Why this matters...